For the first time, a team of scientists has used artificial intelligence to create a useful drug.
The drug, which is meant to treat obsessive compulsive disorder, is now being tested in clinical trials.
What is so remarkable about this drug is the process through which it was invented. Using artificial intelligence, researchers took only one year to develop a medication ready for a clinical trial. Traditional drug research methods usually take five years to churn out a workable product. And that is just for the research phase; the next step is to collect clinical data in human trials, which can take time as well.
At the moment, researchers are calling the new drug DSP-1181. A catchier moniker might be given once it passes the human trial phase. In the meantime, clinical data will be gathered to show how effective the medication is in treating OCD. Scientists are hopeful that the drug will be a success.
3 KEY POINTS
- A UK-based AI company called Exscientia and a Japanese pharmaceutical company called Sumitomo Dainippon Pharma collaborated to create the drug.
- This is the first time artificial intelligence has been used to create a new drug.
- The main benefit of using AI in drug development is the speed at which AI can identify useful chemical compounds.